

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Patient Phone: _____
Allergies: _____ Weight lbs/kg: _____ Height: _____

DIAGNOSIS

Diagnosis/ICD 10: _____

Documentation

☐ Demographic info, H&P, insurance info, labs results, 2-3 clinical visit notes (as appropriate)
IV line
Flushing Protocol:

Skilled Nursing Care: Providing medication(s) via venous access or subcutaneous access in accordance with medication orders. Evaluation and documentation of health status, therapy response, and educational needs. Provide support and assistance as required.

MEDICATION	DOSE/STRENGTH	DIRECTIONS FOR USE	QTY	REFILLS
SKYRIZI® Check for SQ and IV	☐ 600 mg for Crohn's ☐ 1,200 mg for UC	Initial Dose: ☐ at week 0, 4, and 8	Initial _____ vials	
	☐ 90 mg/mL PF syringe ☐ 180 mg/1.2mL cartridge ☐ 350 mg/2.4 mL PF _____	Maintenance Dose: ☐ _____ mg SQ on week 12 then every 8 weeks	Maintenance #	
STELARA®	☐ 130mg/26mL vial	☐ _____ mg IV Once	Initial: #	
	☐ 45 mg/0.5 mL PF Syringe ☐ 90 mg/mL PF Syringe	Maintenance Dose: ☐ _____ mg SQ every 8 weeks after initial dose	Maintenance ☐ 1 box	
HUMIRA®	☐ Humira Starter Kit ☐ Adult Crohn's, UC start kit ☐ Pediatric Crohn's start kit	Initial Dose: ☐ 160 mg SQ on day 1, then 80 mg on day 15, ☐ 80 mg SQ on day 1, then 40 mg on day 15	Initial ☐ 1 kit	
	☐ Pen ☐ Prefilled Syringe ☐ Citrate free	Maintenance Dose: ☐ _____ mg SQ every _____ week start on day 29	Maintenance _____ weeks	
☐ REMICADE ☐ INFLECTRA ☐ RENFLEXIS ☐ INFLIXIMAB	☐ 100 mg vial (Round the dose as per closest vial sizes)	Initial Dose: ☐ 5 mg/kg = _____ mg IV at week 0, 2, and 6	Initial #:	
		Maintenance Dose: ☐ _____ mg IV every 8 weeks	Maintenance #	
RINVOQ ER TABLET	☐ 15 mg ☐ 30 mg ☐ 45 mg	Loading Dose: ☐ Daily orally for _____ weeks	Loading ☐ _____ tabs	
		Maintenance Dose: ☐ Daily orally for _____ weeks	Maintenance ☐ _____ tabs	
TREMFYA®	☐ 200 mg vial ☐ 100 mg/mL PF syringe ☐ 200 mg/2 mL PF syringe ☐ 100 mg/mL Pen	Initial Dose: ☐ Infuse 200 mg IV at week 0, 4, and 8	Initial #	

	☐ 200 mg/2mL Pen	Maintenance Dose: ☐ 100 mg SQ every 8 weeks starting week 16 ☐ 200 mg SQ every 8 weeks starting week 12	Maintenance #	
TYSABRI®	☐ 300 mg/15 mL vial	☐ Infuse 300 mg IV every 4 weeks	Quantity #	
OTHER				

PROVIDER INFORMATION

Disclaimer: Mercy LTC & Specialty Pharmacy and its representatives are authorized to provide medical necessity attestations, secure coverage, initiate the prior authorization process, and collect and submit lab results and other patient data as part of the authorization process as my authorized agent. This authorization is valid until revoked in writing by me. Mercy LTC & Specialty Pharmacy may also forward this information and any related materials related to the coverage of this product to the insurer's provider network if it cannot fulfill this prescription.

Provider/Practice Name:		Contact Person:
Provider NPI:	Phone:	Fax:

Provider Signature	DAW (Dispense as Written)	Date
--------------------	---------------------------	------

Confidentiality Statement: This referral form is intended solely for the use of the individual or entity to whom it is addressed. It contains confidential information that is protected by law. Unauthorized use, disclosure, or distribution of this form is strictly prohibited. If you have received this form in error or were not the intended recipient, please contact Mercy LTC & Specialty Pharmacy immediately at (562) 402-0542 and return or destroy all copies of the form.